I can't recall of the eGFR data has been mentioned previously. Regardless, it is impressive to say the least. Diabetics form the biggest component of the dialysis population. If 208 can not only arrest but reverse renal decline, that is one big feather in RVX's cap. That's the beauty here...multiple ways to potentially get this drug to market....diabetes MACE, CKD and an orphan indication not yet announced. Bfw